bicalutamide has been researched along with everolimus in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodie, AM; Goloubeva, O; Njar, VC; Sabnis, G; Schayowitz, A | 1 |
| Bubley, GJ; Buckle, G; Courtney, KD; Elfiky, A; Hayes, JH; Kantoff, PW; Nakabayashi, M; Oh, WK; Sims, DM; Taplin, ME; Weckstein, D; Werner, L | 1 |
| Beckett, LA; Chow, H; Dall'Era, MA; deVere White, R; Evans, CP; Ghosh, PM; Lara, PN; Li, Y; Pan, CX; Yap, SA | 1 |
| Beggs, RE; Bose, S; Crapuchettes, ME; D'Abronzo, LS; deVere White, RW; Durbin-Johnson, BP; Ghosh, PM; Melgoza, FU; Mudryj, M; Siddiqui, S; Tepper, CG; Vinall, RL | 1 |
1 review(s) available for bicalutamide and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for bicalutamide and everolimus
| Article | Year |
|---|---|
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Sirolimus; Tosyl Compounds; Treatment Outcome | 2012 |
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; TOR Serine-Threonine Kinases; Tosyl Compounds | 2016 |
3 other study(ies) available for bicalutamide and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; Anilides; Animals; Benzimidazoles; Castration; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Everolimus; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptor Cross-Talk; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays | 2010 |
The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Everolimus; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice, Nude; Nitriles; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Purines; Receptors, Androgen; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays | 2017 |